Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Intravenous HRS8179 on Brain Swelling After Large Hemispheric Infarction: a Randomised, Double-blind, Placebo-controlled Phase II Trial

NCT05690711 is registered in ClinicalTrials.gov with Beijing Suncadia Pharmaceuticals Co., Ltd as lead sponsor.

NCT NCT05690711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05690711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Intravenous HRS8179 on Brain Swelling After Large Hemispheric Infarction: a Randomised, Double-blind, Placebo-controlled Phase II Trial
Lead sponsor
Beijing Suncadia Pharmaceuticals Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
April 7, 2023
Completion date
February 27, 2024
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain swelling, large hemispheric infarction